Compare Citius Pharmaceuticals Inc (CTXR) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs FuelCell Energy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while FuelCell Energy Inc trades at $21.97 (market cap $1.54B). The key difference: FuelCell Energy Inc is far larger — about 77× Citius Pharmaceuticals Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FCEL | |
|---|---|---|
Market Cap | $20.01M | $1.54B |
Sector | Health | Industrials |
52-Week High | $1.82 | $36.01 |
52-Week Low | $0.48 | $3.92 |
Enterprise Value | $16.23M | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
FCEL trades at $21.32, up 7.51% in the last 24 hours, with a bearish technical signal and RSI near oversold levels. The company reported a net loss of $187.9 million in 2025, with negative gross and net income margins, though revenue grew to $158.16 million. Recent news highlights partnerships with Siemens and focus on AI-driven power demand, but cash flow from operations remains negative.
The outlook is mixed: analyst consensus is split between Buy and Hold with a $20.75 price target, slightly below current price. Key risks include persistent losses, high cash burn, and competitive pressures in the hydrogen sector. Upside potential hinges on execution of growth initiatives and profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
